Citigroup Inc Solid Biosciences Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.51 - $7.56 $428 - $6,357	-841 Reduced 36.39%	1,470 $1,000
Q2 2022 Aug 10, 2022	SELL	$0.43 - $1.24 $1,469 - $4,238	-3,418 Reduced 59.66%	2,311 $1,000
Q1 2022 May 12, 2022	SELL	$0.74 - $1.79 $14,781 - $35,755	-19,975 Reduced 77.71%	5,729 $7,000
Q4 2021 Feb 10, 2022	BUY	$1.69 - $2.46 $31,552 - $45,928	18,670 Added 265.43%	25,704 $45,000
Q3 2021 Nov 10, 2021	BUY	$2.38 - $3.77 $16,740 - $26,518	7,034 New	7,034 $17,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $30.6M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.